Trial Profile

A retrospective ,multicenter, cohort trial to evaluate the efficacy and safety of telaprevir versus simeprevir based triple therapy in patients with hepatitis C after living donor liver transplantation

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Jan 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Simeprevir (Primary) ; Telaprevir (Primary) ; Peginterferon alfa-2a; Peginterferon alfa-2b; Ribavirin
Indications Hepatitis C
Focus Therapeutic Use

01 Dec 2016 Results assessing efficacy and safety published in the Hepatology Research.
18 Apr 2016 New trial record
01 Mar 2016 Results published in the Hepatology Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com